+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cell Therapy Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797973
The global cell therapy market size attained a value of USD 13.8 billion in 2022. The market is likely to grow at a CAGR of 18.10% during the forecast period of 2023-2031 to attain a value of USD 61.2 billion by 2031.

Cell Therapy Market: Introduction

Cell therapy has emerged as a rapidly growing and innovative segment of the global healthcare industry. It encompasses a diverse range of therapeutic approaches, including regenerative medicine, immunotherapy, and gene therapy, aimed at treating various diseases and disorders by harnessing the power of living cells. The global cell therapy market is anticipated to witness significant growth in the coming years, driven by advancements in biotechnology, increasing investment in research and development, and a rising prevalence of chronic diseases and genetic disorders.

Factors like rising incidence of cancer, cardiovascular diseases, and autoimmune disorders drive the demand for innovative and effective treatment options, are fuelling the growth of the cell therapy market. Developments in gene editing technologies, such as CRISPR/Cas9, have opened new possibilities for cell therapies, offering improved efficacy and safety profiles. Governmental and private investments in cell therapy research have led to a robust pipeline of experimental treatments, which are expected to enter the market in the coming years.

Cell Therapy Market Segmentations

The market can be categorised into cell type, therapy type, therapeutic area, end user, and region.

Market by Cell Type

  • Stem Cell
  • Bone Marrow
  • Blood
  • Umbilical Cord
  • Adipose Derived Stem Cell
  • Others (Placenta, and Non-Specific Cells)
  • Non-Stem Cell
Global Cell Therapy Market by Therapy Type
  • Autologous
  • Allogeneic

Market Breakup by Therapeutic Area

  • Musculoskeletal
  • Cardiovascular
  • Gastrointestinal
  • Neurological
  • Oncology
  • Dermatology
  • Wounds and Injuries
  • Ocular
  • Others

Market Breakup by End User

  • Hospitals and Clinics
  • Regenerative Medicine Centres
  • Diagnostic and Research Centres
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cell Therapy Market Scenario

The cell therapy market is experiencing significant growth, driven by the increasing prevalence of chronic diseases, genetic disorders, and advancements in biotechnology. This burgeoning industry is marked by a highly competitive landscape, with major pharmaceutical and biotechnology companies, as well as smaller players and start-ups, vying for market share. Factors such as substantial investments in research and development, a strong pipeline of investigational therapies, and an expanding awareness of cell therapies' potential contribute to the market's expansion. However, challenges remain in the form of high treatment costs, ethical concerns, and regulatory hurdles. Nevertheless, the cell therapy market holds immense promise for revolutionizing the treatment landscape across various diseases and conditions.

Key Players in the Global Cell Therapy Market

The report gives an in-depth analysis of the key players involved in the cell therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Vericel Corporation
  • Kolon TissueGene Inc
  • JCR Pharmaceuticals Co. Ltd
  • Osiris
  • Stemedica Cell Technologies Inc
  • NuVasive Inc
  • Fibrocell Science Inc
  • Cellectis
  • Praxis Pharmaceutical
  • Genzyme Corporation
  • Advanced Tissue
  • Cells for Cells
  • Novartis AG,
  • GlaxoSmithKline plc,
  • Bone Therapeutics
  • Cell Therapies
Frequently Asked Questions about the Global Cell Therapy Market

What is the estimated value of the Global Cell Therapy Market?

The Global Cell Therapy Market was estimated to be valued at $16.2 Billion in 2023.

What is the growth rate of the Global Cell Therapy Market?

The growth rate of the Global Cell Therapy Market is 18.1%, with an estimated value of $61.2 Billion by 2031.

What is the forecasted size of the Global Cell Therapy Market?

The Global Cell Therapy Market is estimated to be worth $61.2 Billion by 2031.

Who are the key companies in the Global Cell Therapy Market?

Key companies in the Global Cell Therapy Market include Vericel Corporation, Kolon Tissuegene Inc., Jcr Pharmaceuticals Co. Ltd., Medipost Co. Ltd., Osiris, Stemedica Cell Technologies Inc., Nuvasive Inc., Fibrocell Science Inc., Pharmicell Co. Ltd and Anterogen.Co.Ltd..

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell Therapy Market Overview
3.1 Global Cell Therapy Market Historical Value (2016-2022)
3.2 Global Cell Therapy Market Forecast Value (2023-2031)
4 Global Cell Therapy Market Landscape
4.1 Global Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cell Therapy Product Landscape
4.2.1 Analysis by Cell Type
4.2.2 Analysis by Therapy Antigen
4.2.3 Analysis by End User
5 Global Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cell Therapy Market Segmentation
6.1 Global Cell Therapy Market by Cell Type
6.1.1 Market Overview
6.1.2 Stem Cell Bone Marrow Blood Umbilical Cord Adipose Derived Stem Cell Others (Placenta, and Non-Specific Cells)
6.1.3 Non-Stem Cell
6.2 Global Cell Therapy Market by Therapy Type
6.2.1 Market Overview
6.2.2 Autologous
6.2.3 Allogeneic
6.3 Global Cell Therapy Market by Therapeutic Area
6.3.1 Market Overview
6.3.2 Musculoskeletal disorders
6.3.3 Cardiovascular diseases
6.3.4 Neurological disorders
6.3.5 Oncological disorders
6.3.6 Dermatology
6.3.7 Inflammatory and Autoimmune disorders
6.3.8 Others
6.4 Global Cell Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Regenerative Medicine Centers
6.4.4 Diagnostic and Research Centers
6.4.5 Others
6.5 Global Cell Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Supplier Landscape
18.1 Vericel Corporation
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Kolon TissueGene Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 JCR Pharmaceuticals Co. Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 MEDIPOST Co. Ltd.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Osiris
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Stemedica Cell Technologies Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 NuVasive Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Fibrocell Science Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.8.6 Cells for Cells
18.8.7 Financial Analysis
18.8.8 Product Portfolio
18.8.9 Demographic Reach and Achievements
18.8.10 Mergers and Acquisitions
18.8.11 Certifications
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Novartis AG,
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Allogene Therapeutics Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Stempeutics Research Pvt. Ltd
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Cell Therapy Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket

Companies Mentioned

  • Vericel Corporation
  • Kolon Tissuegene Inc.
  • Jcr Pharmaceuticals Co. Ltd.
  • Medipost Co. Ltd.
  • Osiris
  • Stemedica Cell Technologies Inc.
  • Nuvasive Inc.
  • Fibrocell Science Inc.
  • Pharmicell Co. Ltd
  • Anterogen.Co.Ltd.
  • Novartis Ag,
  • Celgene Corpo Ration
  • Allogene Therapeutics Inc.
  • Stempeutics Research Pvt. Ltd